Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ASCENDIS PHARMA A/S

(ASND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ascendis Pharma A/S : INCORPORATION BY REFERENCE (Form 6-K)

09/22/2021 | 05:22pm EST

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-203040,333-210810,333-211512,333-213412,333-214843,333-216883,333-228576 and 333-254101) and Form F-3 (Registration Numbers 333-209336,333-211511,333-216882,333-223134,333-225284 and 333-256571) of Ascendis Pharma A/S (the "Company") (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Based on recent discussions with the European Medicines Agency (the "EMA"), the Company believes that it is on track to obtain a positive opinion on TransCon hGH for the treatment of pediatric growth hormone deficiency from EMA's Committee for medicinal products for human use ("CHMP") in the fourth quarter. European Commission approval for TransCon hGH is expected up to 67 days after the positive CHMP opinion, which the Company expects to occur late this year or in early 2022.

Forward-Looking Statements

This report contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this report regarding Ascendis' future plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the Company's belief that it is on track to obtain a positive opinion on TransCon hGH for the treatment of pediatric growth hormone deficiency from EMA's CHMP in the fourth quarter and the Company's expectation that European Commission approval for TransCon hGH is expected up to 67 days after the positive CHMP opinion, which the Company expects to occur late this year or in early 2022. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: delays in the development of its TransCon hGH program related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; dependence on third party manufacturers to supply study drug; and the effects on its business from the worldwide COVID-19 pandemic. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC") on March 10, 2021 and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future in-licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.

Disclaimer

Ascendis Pharma A/S published this content on 22 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 September 2021 21:21:05 UTC.


ę Publicnow 2021
All news about ASCENDIS PHARMA A/S
11/18Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forwar..
GL
11/18Ascendis Pharma A/S Announces Top-Line Results from Week 84 of Its Phase 2 PaTH Forward..
CI
11/18Ascendis Pharma A/S Elects Rafa?le Tordjman as A Class II Director
CI
11/17Ascendis Pharma A/S to Participate in the Evercore ISI 4th Annual HealthCONx Conference
AQ
11/16European ADRs Mixed in Tuesday Morning Trading
MT
11/15SVB Leerink Adjusts Ascendis Pharma's Price Target to $190 from $182, Keeps Outperform ..
MT
11/15Ascendis Pharma A/S - Share Repurchase Program Update
AQ
11/12Ascendis Pharma Says EMA Panel Issues Positive Opinion Backing Approval of Growth Hormo..
MT
11/12Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon™ hGH for Patients..
GL
11/12Ascendis Pharma A/S Receives Positive CHMP Opinion for TransCon? hGH for Patients with ..
CI
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2021 7,69 M 8,71 M 8,71 M
Net income 2021 -401 M -454 M -454 M
Net cash 2021 677 M 766 M 766 M
P/E ratio 2021 -17,0x
Yield 2021 -
Capitalization 6 866 M 7 772 M 7 770 M
EV / Sales 2021 804x
EV / Sales 2022 90,4x
Nbr of Employees 482
Free-Float 10,5%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 125,12 €
Average target price 171,04 €
Spread / Average Target 36,7%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-15.09%7 772
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.30.33%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530